FWG Holdings LLC Decreases Stake in Johnson & Johnson (NYSE:JNJ)

FWG Holdings LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 43.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,436 shares of the company's stock after selling 3,478 shares during the period. FWG Holdings LLC's holdings in Johnson & Johnson were worth $692,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Altman Advisors Inc. raised its position in shares of Johnson & Johnson by 3.7% during the 1st quarter. Altman Advisors Inc. now owns 10,351 shares of the company's stock worth $1,618,000 after purchasing an additional 367 shares during the last quarter. Cullen Frost Bankers Inc. raised its position in shares of Johnson & Johnson by 0.6% during the 1st quarter. Cullen Frost Bankers Inc. now owns 344,647 shares of the company's stock worth $57,156,000 after purchasing an additional 2,223 shares during the last quarter. Guardian Wealth Advisors LLC raised its position in shares of Johnson & Johnson by 3.9% during the 1st quarter. Guardian Wealth Advisors LLC now owns 6,130 shares of the company's stock worth $1,017,000 after purchasing an additional 231 shares during the last quarter. Parcion Private Wealth LLC raised its holdings in Johnson & Johnson by 23.9% in the 1st quarter. Parcion Private Wealth LLC now owns 9,396 shares of the company's stock valued at $1,558,000 after acquiring an additional 1,812 shares during the last quarter. Finally, DDD Partners LLC lifted its stake in shares of Johnson & Johnson by 50.5% during the 1st quarter. DDD Partners LLC now owns 145,274 shares of the company's stock worth $24,092,000 after purchasing an additional 48,774 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.4%

Johnson & Johnson stock traded up $0.67 during trading on Friday, reaching $163.65. 9,764,459 shares of the company's stock were exchanged, compared to its average volume of 8,146,241. The company's 50-day moving average is $154.10 and its two-hundred day moving average is $154.84. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The firm has a market cap of $393.75 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 2.21 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the company earned $2.82 EPS. The firm's revenue was up 5.8% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on JNJ shares. Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, UBS Group reaffirmed a "buy" rating and issued a $190.00 price objective (up previously from $180.00) on shares of Johnson & Johnson in a research report on Thursday. Eleven research analysts have rated the stock with a hold rating, nine have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $174.11.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.